Multiple Myeloma Clinical Trials in Louisville, Kentucky

7 studies are recruiting for multiple myeloma in Louisville, Kentucky right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

    This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Norton Healthcare, Inc., Louisville, Kentucky
    Locations
    24 in total
    Run by
    Heidelberg Pharma AG

    See if you can join NCT04879043 on ClinicalTrials.gov

  2. Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

    The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Norton Women's and Children's Hospital, Louisville, Kentucky
    Locations
    52 in total
    Run by
    Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

    See if you can join NCT06297226 on ClinicalTrials.gov

  3. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

    The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Norton Cancer Institute, Louisville, Kentucky
    Locations
    270 in total
    Run by
    Janssen Research & Development, LLC

    See if you can join NCT05552222 on ClinicalTrials.gov

  4. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

    The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Norton Cancer Institute, Louisville, Kentucky
    Locations
    144 in total
    Run by
    Janssen Research & Development, LLC

    See if you can join NCT07258511 on ClinicalTrials.gov

  5. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

    The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Norton Cancer Institute, Louisville, Kentucky
    Locations
    151 in total
    Run by
    Janssen Research & Development, LLC

    See if you can join NCT07518186 on ClinicalTrials.gov

  6. A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

    This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with autologous stem cell transplantation (transplant-eligible) or ineligible for …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Norton Cancer Institute, Louisville, Kentucky
    Locations
    32 in total
    Run by
    Regeneron Pharmaceuticals

    See if you can join NCT05828511 on ClinicalTrials.gov

  7. Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

    The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs that linvoseltamab can effectively treat cancer. The study is looking at several other research que…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Norton Cancer Institute, Louisville, Kentucky
    Locations
    40 in total
    Run by
    Regeneron Pharmaceuticals

    See if you can join NCT03761108 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.